Stock of The Day: What’s Propelling Momenta Pharmaceuticals, Inc. to Decline So Much?

Stock of The Day: What's Propelling Momenta Pharmaceuticals, Inc. to Decline So Much?

The stock of Momenta Pharmaceuticals, Inc. (NASDAQ:MNTA) is a huge mover today! About 541,904 shares traded hands or 1.40% up from the average. Momenta Pharmaceuticals, Inc. (NASDAQ:MNTA) has risen 54.13% since March 9, 2016 and is uptrending. It has outperformed by 46.72% the S&P500.
The move comes after 8 months negative chart setup for the $1000.00 million company. It was reported on Oct, 12 by Barchart.com. We have $11.81 PT which if reached, will make NASDAQ:MNTA worth $60.00 million less.

Analysts await Momenta Pharmaceuticals, Inc. (NASDAQ:MNTA) to report earnings on November, 2. They expect $-0.28 earnings per share, up 36.36% or $0.16 from last year’s $-0.44 per share. After $-0.31 actual earnings per share reported by Momenta Pharmaceuticals, Inc. for the previous quarter, Wall Street now forecasts -9.68% EPS growth.

Momenta Pharmaceuticals, Inc. (NASDAQ:MNTA) Ratings Coverage

Out of 8 analysts covering Momenta Pharmaceuticals (NASDAQ:MNTA), 5 rate it a “Buy”, 2 “Sell”, while 1 “Hold”. This means 63% are positive. Momenta Pharmaceuticals has been the topic of 16 analyst reports since August 6, 2015 according to StockzIntelligence Inc. The stock has “Outperform” rating given by Leerink Swann on Wednesday, May 4. On Monday, November 23 the stock rating was initiated by Barclays Capital with “Equal-Weight”. JP Morgan initiated it with “Overweight” rating and $26 target price in Friday, November 13 report. Goldman Sachs downgraded the shares of MNTA in a report on Thursday, August 6 to “Neutral” rating. The firm has “Sell” rating by Maxim Group given on Wednesday, September 7. On Tuesday, October 13 the stock rating was maintained by Leerink Swann with “Outperform”. Maxim Group upgraded the stock to “Hold” rating in Friday, January 8 report. As per Tuesday, October 11, the company rating was upgraded by Barclays Capital. The rating was initiated by Goldman Sachs with “Neutral” on Monday, June 6.

According to Zacks Investment Research, “Momenta Pharmaceuticals, Inc. is a biotechnology company specializing in the detailed structural analysis and design of complex sugars for the development of improved versions of existing drugs, the development of novel drugs and the discovery of new biological processes. Momenta is also utilizing its ability to sequence sugars to create technology-enabled generic products.”

Insitutional Activity: The institutional sentiment increased to 1.38 in 2016 Q2. Its up 0.21, from 1.17 in 2016Q1. The ratio increased, as 23 funds sold all Momenta Pharmaceuticals, Inc. shares owned while 30 reduced positions. 15 funds bought stakes while 58 increased positions. They now own 57.30 million shares or 1.40% less from 58.11 million shares in 2016Q1.
Blackrock Invest Ltd Co reported 286,945 shares or 0% of all its holdings. Moreover, Qs Invsts Lc has 0.03% invested in Momenta Pharmaceuticals, Inc. (NASDAQ:MNTA) for 277,058 shares. Voya Inv Ltd Co holds 0% or 26,950 shares in its portfolio. Dekabank Deutsche Girozentrale has invested 0% of its portfolio in Momenta Pharmaceuticals, Inc. (NASDAQ:MNTA). Moreover, Vanguard Grp has 0% invested in Momenta Pharmaceuticals, Inc. (NASDAQ:MNTA) for 4.75 million shares. Ls Inv Advsrs Ltd holds 0% or 2,648 shares in its portfolio. Kcg Hldg Inc holds 0% of its portfolio in Momenta Pharmaceuticals, Inc. (NASDAQ:MNTA) for 16,743 shares. The Pennsylvania-based Sei Invs has invested 0% in Momenta Pharmaceuticals, Inc. (NASDAQ:MNTA). Capstone Asset Management has 18,183 shares for 0.01% of their US portfolio. Blackrock Advisors Ltd Liability Corp last reported 0% of its portfolio in the stock. Renaissance Lc has 0.01% invested in the company for 364,670 shares. Senzar Asset Mgmt Lc reported 808,198 shares or 0% of all its holdings. Discovery Cap Management Limited Ct accumulated 1.12% or 4.50M shares. Laurion Capital Mgmt L P has invested 0% of its portfolio in Momenta Pharmaceuticals, Inc. (NASDAQ:MNTA). Panagora Asset Mngmt Incorporated last reported 5,722 shares in the company.

Insider Transactions: Since April 18, 2016, the stock had 0 buys, and 12 sales for $314,999 net activity. $11,116 worth of Momenta Pharmaceuticals, Inc. (NASDAQ:MNTA) was sold by Roach James M.. $12,415 worth of Momenta Pharmaceuticals, Inc. (NASDAQ:MNTA) shares were sold by Leicher Bruce. 2,843 Momenta Pharmaceuticals, Inc. (NASDAQ:MNTA) shares with value of $27,208 were sold by Bishop John E. Shea Richard P sold $11,717 worth of stock or 972 shares. Shares for $10,690 were sold by Kaundinya Ganesh Venkataraman. $67,600 worth of Momenta Pharmaceuticals, Inc. (NASDAQ:MNTA) shares were sold by Shapiro Bennett M. WHEELER CRAIG A sold $70,704 worth of stock.

More notable recent Momenta Pharmaceuticals, Inc. (NASDAQ:MNTA) news were published by: Fool.com which released: “Why Momenta Pharmaceuticals, Inc. Jumped Higher Today” on October 11, 2016, also Fool.com with their article: “Momenta Pharmaceuticals, Inc.: Good News from Courts and the FDA Ahead?” published on August 09, 2016, Fool.com published: “Momenta Pharmaceuticals Inc. Shed a Third of Its Value in February — Here’s Why” on March 04, 2016. More interesting news about Momenta Pharmaceuticals, Inc. (NASDAQ:MNTA) were released by: Fool.com and their article: “Why Momenta Pharmaceuticals, Inc. Was Up Today” published on January 08, 2016 as well as Fool.com‘s news article titled: “Why Momenta Pharmaceuticals, Inc. Earned a Lower Price Today” with publication date: February 18, 2016.

MNTA Company Profile

Momenta Pharmaceuticals, Inc., incorporated on May 17, 2001, is a biotechnology company. The Firm is focused on developing generic versions of drugs, biosimilars and therapeutics for oncology and autoimmune disease. The Firm focuses on three product areas: Complex Generics, Biosimilars and Novel Therapeutics. The Firm has developed generic version of Lovenox (enoxaparin sodium injection).

Receive News & Ratings Via Email - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings with our FREE daily email newsletter.

Leave a Comment